CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.

Melissa Lynne Johnson,Anthony B. El-Khoueiry,Navid Hafez,Nehal J. Lakhani,Hirva Mamdani,Jordi Rodon Ahnert,Rachel E. Sanborn,Thang Ho,Rachel Li,Jana Waldes,Alexander I. Spira

CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.

2020

Melissa Lynne Johnson
Anthony B. El-Khoueiry
Navid Hafez
Nehal J. Lakhani
Hirva Mamdani
Jordi Rodon Ahnert
Rachel E. Sanborn
Thang Ho
Rachel Li
Jana Waldes
Alexander I. Spira

3502Background: CX-2029 is a PROBODY drug conjugate (PDC) of MMAE, a potent microtubule inhibitor, directed against CD71 (transferrin receptor 1). In addition to being an abundant tumor antigen, CD...

Keywords:

advanced cancer
first in human
in patient
Conjugate
Transferrin receptor
Pathology
Drug
Medicine
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations